Jefferies Lowers Gerresheimer to Hold, Cites Acquisition Execution and Result Delays as Key Overhangs
Jefferies downgraded Gerresheimer to Hold and cut its price target to c26.80 from c34.10, citing persistent market overhangs and repeated delays in reporting results. The broker also kept a Hold rating on Schott Pharma. Analysts flagged execution risk tied to Gerresheimers acquisition of Bormioli Pharma, slower-than-expected capacity ramp-ups an…